Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
18 years of age, male or female;
The Participants was diagnosed with novel coronavirus pneumonia;
It meets the heavy-duty standards of the new coronavirus pneumonia diagnosis and treatment protocol (version 9).
Participants who voluntarily sign informed consent.
The National Institute of Allergy and Infectious Diseases Sequential Scale (NIAID-0S) score is 5 or 6;
You may not be if
Participants who cannot take orally, or are suspected to be allergic to Jaktinib, similar drugs or their excipients, or have severe gastrointestinal dysfunction that affects drug absorption;
Participants who have received the following treatments within the specified time window before randomization:
1. Participants have received Janus kinase (JAK) inhibitor, interleukin 6 (IL-6) inhibitor, IL-1 inhibitor, tumor necrosis factor (TNF) inhibitor, T cell or B cell depletion agent, interferon and other immunosuppressive drugs within the first two weeks of randomization, except glucocorticoid;
2. Systematically used CYP 3A4 potent inhibitor or potent inducer in the first five drug half lives at random;
